Journal
DRUGS
Volume 69, Issue 2, Pages 223-240Publisher
ADIS INT LTD
DOI: 10.2165/00003495-200969020-00006
Keywords
-
Categories
Ask authors/readers for more resources
Sorafenib (Nexavar (R)) is an orally active multikinase inhibitor that is approved in the EU for the treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall survival and delays the time to progression in patients with advanced hepatocellular carcinoma who are not candidates for potentially curative treatment or transarterial chemoembolization. Sorafenib is generally well tolerated in patients with advanced hepatocellular carcinoma. Thus, sorafenib represents an important advance in the treatment of advanced hepatocellular carcinoma and is the new standard of care for this condition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available